

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

18 April 2006

Dear Sir,

Canadian Regulatory Clearance by Health Canada for FerriScan®

Perth, Australia, Tuesday 18 April 2006: Resonance Health Limited (ASX:RHT) announced today that it had been granted Canadian regulatory clearance by Health Canada for FerriScan®, its novel non-invasive diagnostic test for liver iron concentration.

The regulatory clearance allows RHT to market the FerriScan test in Canada where an estimated 150,000 people are afflicted with iron overload disorders such as haemochromatosis and thalassaemia.


Health Canada clearance for FerriScan follows the achievement of U.S. Food and Drug Administration (FDA) marketing clearance, the listing of FerriScan by the Australian Therapeutic Goods Administration (TGA), and achievement of European CE Mark.

"Health Canada marketing clearance is a significant milestone for RHT. Canada is a sophisticated market where clinicians see FerriScan as a major advancement in the way they can measure and monitor iron levels in patients. As we are currently doing in other parts of the world, we will partner with leading hospitals, diagnostic imaging centres, clinicians and patient advocacy groups in Canada to offer the FerriScan test to the public. In doing so we believe the Canadian market will be a strategic segment in the overall achievement of the business goals for FerriScan" said Dr James Williams, Managing Director of Resonance Health Limited.

About 'Iron Overload' Conditions

Having too much iron in the body and being unable to get rid of this excess is one of the world's most common hereditary disorders. The disorders, often collectively termed as 'Iron Overload', are generally classified as primary (e.g. hereditary haemochromatosis – HHC) or secondary (e.g. acquired – transfusional iron overload such as thalassaemia). Approximately 11 million people globally, who have 'clinically significant' iron loading would benefit from improved diagnosis and management of their condition.

Haemochromatosis is a genetic disorder that causes iron deposition in the liver and other organs of the body, resulting in iron overload. The condition frequently remains undiagnosed because of lack of awareness, its long latency period, and its non-specific symptoms. Thalassaemia, a genetic blood disorder and a very severe and debilitating form of anaemia, also results in iron overload due to the requirement for frequent blood transfusions.



About Resonance Health Ltd

Resonance Health (ASX: RHT) is an Australian healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI)-related technology for the quantitative measurement of iron levels in the human body. Our mission is to develop and market our technologies to assist in the diagnosis and management of patients suffering from iron-related conditions, whilst delivering significant added value for our MRI customers who deliver our service through their networks.

In 2005, RHT began the global commercial launch of FerriScan®, its world-leading non-invasive tool for measuring liver iron levels.

The FerriScan service involves an MRI scan followed by off-site processing of the images by RHT using its patented methodology to generate the liver iron concentration result. MR data is transmitted electronically via a secure data process to the RHT analysis centre from anywhere in the world. The test requires no new equipment purchase at the MRI centre level. FerriScan provide a significant improvement over current blood markers and invasive surgical procedures. This improvement leads to increased clinical efficiency and accuracy in diagnosis, in addition to allowing optimisation of treatment programs for iron-related disorders such as hereditary haemochromatosis and thalassemia. FerriScan is now positioned to become a routine part of the clinical diagnosis and management of iron loading disorders as well as playing a major role in the testing and monitoring of drugs used to treat these conditions.

FerriScan has received regulatory clearance to be marketed in the US, Australia, UK and Europe. Further information about Resonance Health and FerriScan can be obtained from the following websites: www.resonancehealth.com and www.ferriscan.com.

Media and investor relations	Resonance Health
Rebecca Piercy Buchan Consulting T - +61 3 9866 4722 M - +61 422 916 422 Email: rpiercy@bcg.com.au	Dr James Williams Managing Director Resonance Health Limited T - +61 8 9286 5300 M - +61 409 050 519 Email: jamesw@ferriscan.com